

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

Nicholas C. Nicolaides, Luigi Grasso,  
and Philip M. Sass

**Serial No.:** 09/707,468

**Group Art Unit:** 1644


**Filing Date:** November 7, 2000

**Examiner:** Not assigned

**For:** METHODS FOR GENERATING GENETICALLY ALTERED ANTIBODY-  
PRODUCING CELL LINES WITH IMPROVED ANTIBODY  
CHARACTERISTICS

DATE OF DEPOSIT: March 7, 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID  
ON THE DATE INDICATED ABOVE AND IS ADDRESSED  
TO BOX SEQUENCE, ASSISTANT COMMISSIONER FOR  
PATENTS, WASHINGTON, DC 20231.

  
TYPED NAME: Patrick J. Farley  
REGISTRATION NO.: 42,524

**BOX SEQUENCE**

Assistant Commissioner for Patents  
Washington DC 20231

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE**

In response to the "Notice to Comply With Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated January 11,  
2001, a response to which is due March 11, 2001, enclosed herewith is:

- Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821  
through 1.825;
- Substitute pages of the Sequence Listing;
- Substitute copy of the computer readable form of amended Sequence Listing;

*SEARCHED*  
*MAR 1 1 2001*

- Copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- Petition for Extension of Time;
- Other: Copy of executed Declaration filed separately on February 22, 2001.

The Commissioner is hereby authorized to charge any underpayment associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in duplicate.


Date: *March 7, 2001*

*Patrick J. Farley*  
\_\_\_\_\_  
Patrick J. Farley  
Registration No. 42,524

Woodcock Washburn Kurtz  
Mackiewicz & Norris LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

**RAW SEQUENCE LISTING  
ERROR REPORT**

BIOTECH  
SYSTEMS  
BRANCH



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/707,468

Source: OPIE

Date Processed by STIC: 11/22/2000

RECEIVED  
OPIE/JCWS  
DEC 14 2000

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin30help@uspto.gov](mailto:patin30help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

**Checker Version 3.0**

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a clean and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated from the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be downloaded from the USPTO website at the following address:  
<http://www.uspto.gov/web/offices/pac/checker>

# Sequence Listing Error Summary

<u>ERROR DETECTED</u>	<u>SUGGESTED CORRECTION</u>	<u>SERIAL NUMBER:</u>
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE		
1 <input type="checkbox"/> Wrapped Nucleic	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".	
2 <input type="checkbox"/> Wrapped Aminos	The amino acid number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".	
3 <input type="checkbox"/> Incorrect Line Length	The rules require that a line not exceed 72 characters in length. This includes spaces.	
4 <input type="checkbox"/> Misaligned Amino Acid Numbering	The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.	
5 <input type="checkbox"/> Non-ASCII	This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text, so that it can be processed.	
6 <input type="checkbox"/> Variable Length	Sequence(s) <input type="checkbox"/> contain n's or Xaa's which represented more than one residue. As per the rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.	
7 <input type="checkbox"/> PatentIn ver. 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) <input type="checkbox"/> Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
8 <input type="checkbox"/> Skipped Sequences (OLD RULES)	Sequence(s) <input type="checkbox"/> missing. If intentional, please use the following format for each skipped sequence (2) INFORMATION FOR SEQ ID NO:X: (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS") (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).	
9 <input type="checkbox"/> Skipped Sequences (NEW RULES)	Sequence(s) <input type="checkbox"/> missing. If intentional, please use the following format for each skipped sequence <210> sequence id number <400> sequence id number 000	
10 <input checked="" type="checkbox"/> Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220> to <223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
11 <input type="checkbox"/> Use of <213>Organism (NEW RULES)	Sequence(s) <input type="checkbox"/> are missing this mandatory field or its response.	
12 <input type="checkbox"/> Use of <220>Feature (NEW RULES)	Sequence(s) <input type="checkbox"/> are missing the <220>Feature and associated headings. Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown". Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1 823 of new Rules)	
13 <input type="checkbox"/> PatentIn ver. 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other means to copy file to floppy disk.	



1. LAW & POLITICAL DIGESTS

Mr. Martin J. Murphy  
300 CPB 122-2007-12-07465-111W

THE ALDINE LISTING

At: Mori.MG31.app  
Subject: CRB 1121.01 17.10.2012

## ANSWERING THE CALL FOR INTEGRATION

At: Mailbox 1000  
In: Box 1000 - 1000-2746-1138

REGULATORY ENZYME ACTIVATION

Mr. M. J. O'Farrell  
Mr. J. H. Gleeson, Jr., Esq.

## THEORY AND PRACTICE

As: May 1, 1911 - 10:00 A.M.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/707,468	11/07/2000	Nicholas C. Nicolaides	MOR-0003

**FORMALITIES LETTER**



\*OC00000005672887\*

Patrick J Farley  
Woodcock Washburn Kurtz Mackiewicz & Norris LLP  
One Liberty Place-46th Floor  
Philadelphia, PA 19103

Date Mailed: 01/11/2001

**NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION**

**FILED UNDER 37 CFR 1.53(b)**

*Filing Date Granted*

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).


- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason (s):
  - This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- PatentIn Software Program Support
  - - For Technical Assistance, call (703) 287-0200
  - - To Purchase PatentIn Software, call (703) 306-2600

- The balance due by applicant is \$ 130.

*A copy of this notice MUST be returned with the reply.*

  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART I - ATTORNEY/APPLICANT COPY